Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis.

Yunwei LIU; Yanxin CHEN; Zhimin ZENG; Anwen LIU

Immune checkpoint inhibitors (ICIs) is a negative regulatory factor antibody, which activates T cells to play an anti-tumor effect in immunotherapy, and can also cause immune-related adverse responses, thereby inducing a series of immune related adverse events (irAEs). Among these irAEs, although the incidence of ICIs-related myocarditis is very low, the fatality rate is significantly higher than other adverse reactions, close to 50%. Clinicians should be vigilant when applying ICIs, but the pathogenesis of ICIs-related myocarditis is still unclear. This article combines the recent research results of ICIs to summarize the mechanism and clinical manifestations of ICIs-related myocarditis, so as to improve clinicians' understanding of the adverse reactions.

CARDIOTOXICITY; IMMUNE checkpoint inhibitors; IMMUNOGLOBULINS; CARDIOMYOPATHIES; DRUG side effects; MEDICAL research; IMMUNOTHERAPY

Chinese Journal of Lung Cancer, 2021, Vol 24, Issue 9, p668

1009-3419

Academic Journal

10.3779/j.issn.1009-3419.2021.102.27